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Objective: To evaluate vascular endothelial growth factor (VEGF) levels in hepatocel-
lular carcinoma patients before and after transcatheter arterial chemoembolization
(TACE) and percutaneous ethanol injection (PEI) and its relation to treatment response.
Methods: A total of 40 patients with unrespectable hepatocelluar carcinoma were
assessed clinically. Twenty patients were suitable to be treated by TACE, while other 20
patients were treated with PEI. Serum VEGF levels were measured before and 1 month
after each procedure by ELISA. Response was assessed after 1 month according to Union
Internationale Contre le Cancer evaluation criteria based on change in tumor size as
measured by ultrasound.
Results: There was no signiﬁcant difference between TACE and PEI groups with regard
to age, sex, tumor size, response to local therapy, or VEGF and alpha-fetoprotein before
and after therapy. VEGF levels after TACE were signiﬁcantly higher than before TACE
[(298.1 ± 123.6) pg/mL vs. (205.8 ± 307.3) pg/mL; P = 0.001]. Also, VEGF levels were
signiﬁcantly higher after PEI than before PEI [(333.8 ± 365.6) pg/mL vs. (245.3 ± 301.8)
pg/mL; P = 0.000]. Non-responders of both groups had signiﬁcantly high VEGF levels
than responder's, both before [(985.0 ± 113.2) pg/mL vs. (117.1 ± 75.3) pg/mL;
P < 0.001] and after therapy [(1330.6 ± 495.7) pg/mL vs. (171.0 ± 94.7) pg/mL;
P = 0.000)].
Conclusions: Both TACE and PEI were associated with an increase in serum VEGF in
hepatocelluar carcinoma patients. Higher levels of VEGF before and after therapy were
found in non-responders, suggesting that VEGF is a useful marker in predicting treatment
response.1. Introduction
Hepatocellular carcinoma (HCC) is one of the most common
malignant tumors worldwide and it is the 3rd common cause of
cancer-related death [1]. In Egypt, with high prevalence of
hepatitis C virus (HCV), HCC is reported as the most
common cancer among males [2]. Although surgical resection
and liver transplantation are the curative treatment for HCC,
these options are usually limited due to poor surgical ﬁtness,inoperable lesion and shortage of liver donors [3]. Many of
current non-surgical interventions improved survival and pro-
vided effective bridging therapy for liver transplantation [4].
Although radiofrequency ablation (RFA) is the ﬁrst choice
procedure for HCC treatment, percutaneous ethanol injection
(PEI) is still a valuable option for small uninodular HCC
especially in sites where thermal ablation is risky [3,5]. In
addition, PEI is a simple, safe, effective, and cheap treatment
with low complication rate [6]. Transcatheter arterial
chemoembolization (TACE) is a safe procedure with a
morbidity of less than 5% and mortality of 0.6% [7]. TACE
alone or with other procedures as adjuvant therapy or before
surgical treatment is currently used in patients with
multinodular HCC, without vascular invasion or extrahepatic
spread and well preserved liver function [8]. Vascularopen access article under the CC BY-NC-ND
Table 1
Baseline clinicopathological characteristics of 40 patients with HCC.
Characteristics n (%)
Age (years) < 60 20 (50.0)
> 60 20 (50.0)
Sex Male 34 (85.0)
Female 6 (15.0)
Virology HCV 33 (82.5)
Child-Pugh class A 32 (80.0)
B 8 (20.0)
UICC/AJCC staging IIIA 13 (32.5)
IIIB 27 (67.5)
Performance status 1 13 (32.5)
2 27 (67.5)
Tumor size (cm) 2–5 32 (80.0)
> 5 8 (20.0)
AFP (ng/mL) < 400 31 (77.5)
> 400 9 (22.5)
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angiogenic factors, which has been reported to be correlated
with tumor metastasis, aggressiveness and poor prognosis in
patients with HCC [9,10]. Recently, some studies demonstrated
changes in VEGF after some locoregional therapies [11,12].
However, the relation of these changes to efﬁcacy of therapy
needs further evaluation. This study was conducted to evaluate
VEGF level in HCC patients before and after TACE and PEI
and its relation to treatment response.
2. Materials and methods
2.1. Study population
A total of 40 patients with HCC were included in this pro-
spective study who were presented to National Cancer Institute
and Internal Medicine Department of Kasr-Al Ainy Hospital in
the period between September 2010 and February 2011.
Enrollment criteria were: (1) absence of previous treatment for
HCC, (2) unidimensionally and/or bidimensionally measurable
Okuda stage I/II tumors, (3) pathologically proven lesion and (4)
patients between 18 and 70 years of age and have Eastern
Cooperative Oncology Group performance score 0–2 and an
anticipated life expectancy of at least 8 weeks [13]. Twenty
patients were eligible to PEI based on following criteria of
their lesions: (1) less than 3 lesions, (2) well deﬁned, (3)
capsulated and (4) not near to liver surface. Another 20
patients were candidates for TACE with following selection
criteria: (1) patency of portal vein, (2) absence of extrahepatic
metastasis and (3) stage A or B Child-Pugh classiﬁcation.
Prior written informed consent was obtained from each patient
and approval of local ethical committee was given before
starting the study. All patients were evaluated clinically and with
complete blood count, coagulation proﬁle, and liver function.
Disease stage was determined based on Union Internationale
Contre le Cancer (UICC)/American Joint Committee on Cancer
(AJCC) staging system [14]. Serum VEGF and serum alpha-
fetoprotein (AFP) were measured before and 1 month after the
procedures. Response to therapy was deﬁned by standard UICC
criteria based on the change in tumor size as assessed by ul-
trasound 1 month after the procedure. Collectively, patients who
had complete remission, partial remission or stable disease were
considered as responders, while those with progressive disease
were considered as non-responders.
2.2. TACE procedure
An arterial catheter was inserted into the femoral artery by
Seldinger method and placed in the hepatic artery. Tumor-feeding
vessels were super-selected as possible and the catheter was
inserted to the level of the segmental arteries, subsegmental arteries
or lobar branches. A solution containing 50 mg of doxorubicin
hydrochloride and 10 mL of ionized oil (lipidol) was infused
through the catheter (5 French) or microcatheter (2.8 or 3 French).
2.3. PEI procedure
Under ultrasound guidance and after local anesthesia, a 22
gauge percutaneous transhepatic cholangiogram needle was
inserted into the tumor. Absolute (99.5%) ethanol was injected
at a dose of 2–10 mL.2.4. Assay of serum VEGF level
Serum VEGF concentrations were quantitatively measured
using ELISA kit (Quantikine Human VEGF Immunoassay;
R&D Systems, Minneapolis, Minnesota, USA) according to
manufacturer's instructions.
2.5. Statistical analysis
Data were analyzed using SPSS 17.0 statistical software.
Numerical data were expressed as mean ± SD or median and
ranged as appropriate. Qualitative data were expressed as fre-
quency and percentage. Chi-square test was used to examine the
relation between qualitative variables. For quantitative data,
comparison between 2 groups was done using Mann–Whitney
test or t-test. Comparison between 3 groups was done using
Kruskal–Wallis test then post-hoc “Scheffe test” on the rank of
variables was used for pair-wise comparison. Comparison of two
repeated measures was done using Wilcoxon signed-rank test. A
P-value < 0.05 was considered signiﬁcant.
3. Results
3.1. Baseline clinicopathological characteristics
As shown in Table 1, patients included 34 males (85.0%) and
6 females (15.0%); age ranged from 54 to 69 years with a me-
dian of 61 years. Thirty-two patients were child A (80.0%) and 8
were child B (20.0%) classiﬁcation. HCC etiology was related to
HCV in 33 patients (82.5%) and hepatitis B virus in 7 patients
(17.5%). According to UICC/AJCC staging system, 13 patients
(32.5%) were stage IIIA and 27 patients (67.5%) were stage
IIIB.
3.2. Clinical and pathological variables in TACE group
compared to PEI
Comparison of clinical and pathological variables in TACE
and PEI groups was presented in Table 2. There was no statis-
tically signiﬁcant difference between the 2 groups regarding age,
sex, virology, Child-Pugh class, tumor size, AFP levels before
(AFP-B), AFP after treatment, VEGF before (VEGF-B) or after
(VEGF-A) therapy or response to local treatment.
Table 2
Clinical and laboratory variables in TACE group compared to PEI group (n = 20). n (%).
Group Age (years) Sex HCV
positive
Child-Pugh
class
Tumor size
(> 5 cm)
AFP
(> 400 ng/mL)
VEGF
(pg/mL) (mean ± SD)
Responders
< 60 > 60 Male Female A B Before
therapy
After
therapy
Before
therapy
After
therapy
Before
therapy
After
therapy
TACE
group
11 (55) 9 (45) 16 (80) 4 (20) 16 (80) 16 (80) 4 (20) 5 (25) 3 (15) 5 (25) 5 (25) 205.8 ± 307.3 298.1 ± 488.9 18 (90)
PEI
group
9 (45) 11 (55) 18 (90) 2 (10) 17 (85) 16 (80) 4 (20) 3 (15) 3 (15) 4 (20) 4 (20) 245.3 ± 301.8 333.8 ± 365.6 17 (85)
P-value 0.53 0.66 1.00 1.00 0.69 1.00 1.00 1.00 0.13 0.15 1.00
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between responders and non-responders
There was no statistically signiﬁcant difference between re-
sponders and non-responders regarding age, virology, tumor
stage, Child-Pugh class and type of local therapy or response.
About 80% of non-responders had initial tumor size > 5 cm
compared to only 11.4% of responders (P = 0.003). All non-
responders had AFP levels > 400 ng/mL compared to 11.4%
of responders (Table 3).
3.4. VEGF levels in responders compared to non-
responders
VEGF-B values were signiﬁcantly higher in non-responders
compared to responders [(985.0 ± 113.2) pg/mL vs.
(117.1 ± 75.3) pg/mL; P< 0.001] (Table 3). Also, VEGF-A levels
were signiﬁcantly higher in non-responders than responders
[(1330.6 ± 475.9) vs. (171.0 ± 94.7) pg/mL; P = 0.000] (Table 3).Table 3
Comparison of clinicopathological variables between responders and non-re
Group Age (years) Sex HCV
positive
Child-Pugh
class
Tumor
stage
< 60 > 60 Male Female A B IIIA II
Responders
(n = 35)
16
(45.7)
19
(54.3)
32
(91.4)
3
(8.6)
28
(80.0)
28
(80.0)
7
(20.0)
12
(34.3)
2
(65
Non-
responders
(n = 5)
4
(80.0)
1
(20.0)
2
(40.0)
3
(60.0)
5
(100.0)
4
(80.0)
1
(20.0)
1
(20.0) (80
P-value 0.340 0.010 0.560 1.000 1.000
Table 4
Tumor size, AFP, VEGF pre and post-procedures. n (%).
Local therapy Variable
Chemoembolization Tumor size 2–5 cm
> 5 cm
AFP < 400 ng/mL
> 400 ng/mL
VEGF (mean ± SD)
Ethanol injection Tumor size 2–5 cm
> 5 cm
AFP-B < 400 ng/mL
> 400 ng/mL
VEGF (mean ± SD)
a: P-values were evaluated using Wilcoxon–Mann–Whitney test.3.5. Comparison between pre and post-procedures of
tumor size, AFP, VEGF in TACE and PEI groups
In TACE group, after the procedure the tumor size was sta-
tistically signiﬁcant smaller and VEGF levels were signiﬁcantly
higher than before the procedure (P = 0.023, P = 0.001, by
Wilcoxon–Mann–Whitney test). Also, VEGF signiﬁcantly
increased after PEI (P = 0.000, Wilcoxon–Mann–Whitney test).
There was no signiﬁcant change in AFP levels after both pro-
cedures (Table 4).
3.6. Relation of VEGF to tumor size and AFP
In TACE group, mean level of VEGF-B was signiﬁcantly
higher in patients with basal AFP > 400 ng/mL than in patients
with AFP < 400 ng/mL (420 vs. 74.1 pg/mL; P = 0.001). Also,
mean VEGF-A was signiﬁcantly higher in patients with basal
AFP > 400 ng/mL than in patients with AFP < 400 ng/mL (389
vs. 115 pg/mL; P = 0.015). No signiﬁcant difference in VEGF-Bsponders. n (%).
Tumor size
(> 5 cm)
AFP
(> 400 ng/mL)
VEGF
(pg/mL)
(mean ± SD)
Type of
therapy
IB Before
therapy
After
therapy
Before
therapy
After
therapy
Before
therapy
After
therapy
TACE PEI
3
.7)
4
(11.4)
2
(5.7)
4
(11.4)
4
(11.4)
117.1 ±
75.3
171.0 ±
94.7
18
(51.4)
17
(48.6)
4
.0)
4
(80.0)
4
(80.0)
5
(100.0)
5
(100.0)
985.0 ±
113.2
1330.6 ±
475.9
2
(40.0)
3
(60.0)
0.003 0.001 0.001 0.001 < 0.001 0.000 1.000
Pre-procedure Post-procedure P-valuea
15 (75) 17 (85) 0.023
5 (25) 3 (15)
15 (75) 15 (75) 0.116
5 (25) 5 (25)
205.8 ± 307.3 298.1 ± 123.6 0.001
17 (85) 17 (85) 0.203
3 (15) 3 (15)
16 (80) 16 (80) 0.431
4 (20) 4 (20)
245.3 ± 301.8 333.8 ± 365.6 0.000
Table 5
Relationships of VEGF levels and tumor size and AFP in TACE group.
Characteristics Number of patients VEGF-B (pg/mL) (mean range) P-value VEGF-A (pg/mL) (mean range) P-value
Tumor size-B (cm) 2–5 15 77.0 (37.4–420.0) 0.349 132.1 (58.0–389.0) 0.349
> 5 5 80.4 (57.6–1155.0) 115.2 (95.2–2165.3)
AFP-B (ng/mL) < 400 15 74.1 (37.4–198.0) 0.001 115.0 (58.0–345.2) 0.015
> 400 5 420.0 (130.0–1155.0) 389.0 (100.0–2165.3)
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to patients with tumor size 2–5 cm (Table 5).4. Discussion
Assessment of tumor response to locoregional therapy is
important and can improve survival in HCC patients. Current
evaluation of treatment response depends on radiological
assessment, although biological changes may be more infor-
mative and earlier than anatomical changes. So, biochemical
markers are demanding for prediction of treatment response.
High pretreatment VEGF was found to predict poor response
and survival in patients undergoing TACE for HCC [15,16]. Same
results have been found in another study in HCC patients
undergoing RFA [17]. To our knowledge, there is no previous
reports in patients receiving PEI. We found that pretreatment
VEGF levels were signiﬁcantly higher in the non-responders
of both TACE and PEI groups compared to responders. VEGF
activates intracellular receptor kinases which result in tumor
growth and new vessel formation leading to more aggressive
tumor with poor prognosis [17]. Although previous studies found
that VEGF increased shortly after TACE with peak levels during
ﬁrst post week and slow decrease thereafter [11,18], our data
demonstrated that VEGF was signiﬁcantly increased 1 month
after both TACE and PEI and levels were signiﬁcantly higher
in non-responders than responders. This goes with the results
of one study that VEGF levels were signiﬁcantly higher in non-
responders at 4 weeks after TACE [19]. Moreover, higher tissue
levels of VEGF were also reported in HCC specimens from
patients who received TACE than those who didn't [20].
Another study found signiﬁcant increase in microvascularity
after TACE in HCC patients [21]. The changes in VEGF levels
after both TACE and PEI may be caused by tissue hypoxia
resulted from tissue damage induced by therapy. Hypoxia
inducible factor has been found to increase transcriptional
activity of serum VEGF [22]. This increase in VEGF may help
the survival of residual tumor cells [23]. Similar ﬁndings were
reported in a recent study of HCC patients who underwent
RFA [12]. This could suggest that changes in VEGF after
locoregional interventions are related to the degree of tissue
necrosis caused by treatment irrespective of the therapeutic
modalities.
Although many studies reported the prognostic signiﬁcance
of AFP in the outcome of HCC after locoregional therapies
[24,25], others have shown its poor detection rate of small residual
tumor size after treatment [26]. In the current study, AFP was
signiﬁcantly higher in non-responders than responders but
there was no signiﬁcant difference in AFP-B and after TACE or
PEI. This may be related to its long half-life which interferes
with signiﬁcant changes in its level after therapy. In our study,
VEGF levels were signiﬁcantly higher in patients with baseline
AFP > 400 ng/mL. This coincides with what was reported that
AFP is a pro-angiogenesis factor, possibly in a VEGF dependentmanner [27]. This can be explained by two recent ﬁndings: ﬁrst,
AFP concentration had signiﬁcant correlation with increased
VEGF-A expression in HCC cells [28]; second, silencing of
AFP expression signiﬁcantly reduced the expression levels of
VEGF [29]. From previously mentioned, VEGF may be a
better marker than AFP for early evaluation of treatment
response.
Although in our study responders had signiﬁcantly higher
tumor size than non-responders, no signiﬁcant difference of
VEGF level was found between patients with tumor size > 5 cm
and those with smaller size. This result seems to contradict one
study reported that tumors measuring > 2 cm had higher VEGF
levels than those < 2 cm [30]. This difference may be related to a
higher cut of point in our study. The current study found
signiﬁcant increase in VEGF after both PEI and TACE.
In addition, non-responders had higher levels of VEGF than
responders. These results suggest VEGF as possible biochemical
marker in HCC patients receiving TACE or PEI and may help in
the selection of patients who need adjuvant therapy. It is worth
to mention that our study has some limitations such as mall
sample size and follow up measurement of VEGF.
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